Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855931 | 0.80 | SLC6A3 (0.41) | PTGDR2MEN1KMT2AMAPTLMNA | |
| SCHEMBL25430779 | 0.79 | SMN1; SMN2 (0.42) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL14215474 | 0.77 | ALDH1A1 (0.40) | PTGDR2MEN1KMT2AMAPTLMNA | |
| SCHEMBL11922677 | 0.77 | PTGDR2 (0.40) | PTGDR2MEN1KMT2AMAPTLMNA | |
| SCHEMBL5539852 | 0.77 | PTGDR2 (0.46) | PTGDR2MEN1KMT2AMAPTLMNA | |
| SCHEMBL11564617 | 0.77 | CYP1A2 (0.46) | PTGDR2MEN1KMT2AMAPTKDM4E | |
| SCHEMBL5517237 | 0.77 | PTGDR2 (0.36) | PTGDR2MAPTGABRR1KDM4EPOLB | |
| SCHEMBL18002772 | 0.75 | — | — | |
| SCHEMBL4093001 | 0.74 | GABRR1 (0.39) | PTGDR2MEN1KMT2AMAPTGABRR1 | |
| SCHEMBL11923125 | 0.73 | PTGDR2 (0.37) | PTGDR2MEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101137653-B | Thiazole-4-carboxamide derivatives as MGLUR5 antagonists | HOFFMANN LA ROCHE | 2012-05-09 | — | — | CN | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| CN-101137653-A | Thiazole-4-carboxamide derivatives as MGLUR5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | PTGDR2 216/4885MEN1 3984/4885KMT2A 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.